HC Wainwright & Co. Reaffirms Buy Rating for Precigen (PGEN)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 15 2025
0mins
Source: NASDAQ.COM
Analyst Recommendation: HC Wainwright & Co. maintains a Buy recommendation for Precigen (NasdaqGS:PGEN), with a projected one-year price target of $8.42/share, indicating a potential upside of 73.68% from its current price of $4.84/share.
Revenue and Earnings Projections: Precigen's projected annual revenue is expected to reach $59 million, reflecting an increase of 829.62%, with a projected non-GAAP EPS of 0.20.
Institutional Ownership Trends: There has been an increase in institutional ownership of Precigen, with 277 funds reporting positions, a rise of 8.63% in the last quarter, and total shares owned increasing by 28.21% to 133,539K shares.
Shareholder Activity: Notable changes in shareholder positions include Patient Capital Management increasing its stake by 38.52%, while LMORX - Patient Opportunity Trust Class R reduced its holdings by 6.25%.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PGEN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PGEN
Wall Street analysts forecast PGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGEN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.460
Low
9.00
Averages
9.00
High
9.00
Current: 4.460
Low
9.00
Averages
9.00
High
9.00
About PGEN
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Precigen Announces PAPZIMEOS as New Standard of Care for RRP Treatment
- Standard of Care Shift: Precigen's consensus paper recommends PAPZIMEOS as the new first-line treatment for adults with recurrent respiratory papillomatosis (RRP), marking a significant shift from repeated surgeries to HPV-targeted immunotherapy, greatly enhancing treatment options for patients.
- Clinical Experience Backing: Authored by 16 leading physicians, the paper emphasizes the safety and efficacy of PAPZIMEOS based on extensive clinical experience and literature review, providing physicians with a clear treatment algorithm aimed at reducing surgical risks for patients.
- Significant Patient Impact: With approximately 27,000 adult RRP patients in the U.S., the FDA approval of PAPZIMEOS offers the first treatment addressing the root cause of the disease, potentially improving patients' quality of life and reducing healthcare burdens significantly.
- Multidisciplinary Care Advocacy: The paper underscores the importance of shared decision-making and multidisciplinary care, promoting early therapy to avoid the risks associated with repeated surgeries, thus providing a more comprehensive management strategy for RRP patients.
Continue Reading
Precigen Receives FDA Approval for PAPZIMEOS, Surpassing 200 Patient Registrations
- Rapid Commercialization: Precigen's PAPZIMEOS, approved by the FDA in August 2025, is now being prescribed nationwide, with patient registrations doubling since November to over 200, reflecting strong market demand and enthusiastic physician engagement.
- Expanded Coverage: PAPZIMEOS is now covered by private health plans for approximately 170 million lives in the U.S., including most major insurers, and is also included under Medicare and Medicaid, significantly enhancing patient access.
- European Market Expansion: The European Medicines Agency has validated the Marketing Authorization Application for PAPZIMEOS, marking a significant step in Precigen's global expansion efforts, which is expected to create new growth opportunities for the company.
- Optimistic Financial Outlook: The company anticipates that its current capital resources will fund operations until cash flow break-even, and with the rapid rollout of PAPZIMEOS, there is substantial potential for future revenue growth, further solidifying its leadership in RRP treatment.
Continue Reading